Tag: Streptococcus agalactiae

Group B Streptococcus (GBS), or *Streptococcus agalactiae*, is the most common cause of bacterial sepsis and meningitis in newborns in the United States. The first line treatment for *Streptococcus agalactiae* is a beta-lactam antibiotic, such as penicillin or ampicillin, though the specific regimen varies depending on the patient's age and clinical scenario.

According to numerous medical guidelines, Group B Streptococcus (GBS), or *Streptococcus agalactiae*, remains highly susceptible to beta-lactam antibiotics, making amoxicillin an effective treatment. This makes amoxicillin a reliable and often-used oral medication for combating infections caused by this bacterium.

Approximately 1 in 4 pregnant women carry Group B strep (GBS) bacteria [1.10.2]. This raises the critical question for clinicians: Does cefdinir cover Group B strep effectively? While it shows in-vitro activity, it is not a recommended first-line treatment [1.2.5, 1.4.1].

While commonly used for treating urinary tract infections (UTIs), the effectiveness of nitrofurantoin against *Streptococcus agalactiae* (GBS) has been a subject of considerable debate in the medical community. For years, guidance regarding whether nitrofurantoin treats *Streptococcus agalactiae* has been mixed, depending on the infection's location and patient's condition.

A May 2025 meta-analysis revealed that when culture methods were used for diagnosis, amoxicillin resistance in Group B Streptococcus (GBS) was 33.8% [2.4.1]. This article explores the question: **Will amoxicillin treat a strep B UTI?**, considering current resistance data and treatment guidelines.